Key Highlights:
- Aspen Aerogels Inc. (ASPN, Financial) reports a Q1 EPS loss, with a notable revenue decline.
- Analysts project significant upside potential based on current price targets.
- Consensus recommendation places ASPN as an "Outperform" stock.
Aspen Aerogels Inc. (ASPN) recently announced its first-quarter financial results, reporting a GAAP EPS loss of $3.67. The company's revenue hit $78.72 million, falling short by $4.03 million and marking a year-over-year decline of 16.7%. Looking ahead, Aspen Aerogels forecasts Q2 revenue to range between $70 million and $80 million, with net losses expected to lie between $11 million and $4 million.
Wall Street Analysts Provide Optimistic Outlook
Investors might find encouragement in the one-year price targets set by 8 analysts, which average at $17.50. This projection includes a high estimate of $32.00 and a low of $11.00, indicating a substantial upside potential of 207.56% from the current share price of $5.69. For a deeper dive into these estimates, visit the Aspen Aerogels Inc (ASPN, Financial) Forecast page.
Brokerage Firms' Consensus and GF Value Insights
The consensus from 9 brokerage firms places Aspen Aerogels Inc. (ASPN, Financial) at an average recommendation of 2.0, denoting an "Outperform" status. The brokerage recommendation scale ranges from 1 (Strong Buy) to 5 (Sell), highlighting ASPN's potential as an investment.
According to GuruFocus estimates, the GF Value for Aspen Aerogels Inc. (ASPN, Financial) over the next year is projected to be $16.05. This suggests an estimated upside of 182.07% compared to the current stock price of $5.69. The GF Value is a robust estimate of the fair trading value, derived from historical trading multiples, past business growth, and future performance forecasts. For more comprehensive information, explore the Aspen Aerogels Inc. (ASPN) Summary page.
